Public release date: 3-Jul-2013 [ | E-mail | Share ] Contact: Sue McGreevey smcgreevey@partners.org 617-724-2764 Massachusetts General Hospital An international research team has used a novel approach to identify genetic factors that appear to influence susceptibility to cholera. The findings by investigators from Massachusetts General Hospital (MGH), the Broad Institute and the International Center for Diarrhal Disease Research, Bangladesh (ICDDR,B) indicate the importance of pathways involved in regulating water loss in intestinal cells and of the innate immune system in the body's response to the bacteria that causes cholera, which affects from 3 to 5 million people each year and causes more than 100,000 deaths. "We sought to understand cholera by studying the genetics of a population that has been affected by the disease for centuries people in the Ganges River Delta of Bangladesh," says Regina LaRocque, MD, of the MGH division of Infectious Diseases, a co-senior author of the report receiving online publication in Science Translational Medicine. "Our findings are just a first step, but they demonstrate how combining ancient history with the current impact of an infectious disease can be a powerful way of identifying human genes that are important to disease outcome." Cholera is contracted by consuming … Continue reading →

Stem Cell Therapy and Regenexx KUSA TV News By: Regenexx … Continue reading →

Risks and benefits of stem cell therapy Tony Velasquez and Karmina Constantino talk to Philippine Stem Cell Society founding member president of Philippine Academy of Aesthetice Academy Dr. Levi John Lansangan and Philippine Medical... By: ANCalerts … Continue reading →

Experience in Stem Cell Therapyคุณแพทได้แชร์ประสบการณ์และผลลัพธ์ที่คุณแม่คุณแพทได้รับการรักษาโดยการฉีด Stem Cellในงาน "Thailand Innovative Medical Tourism"ที่จัดขึ้นในวันเสาร์ที่ 29มิถ... By: Pat R … Continue reading →

By Jeannette I. Andrade Philippine Daily Inquirer Human embryonic stem cells can become any cell in the body. AFP FILE PHOTO At the age of 64, Antonio Villar Jr., chair of the Dangerous Drugs Board (DDB), wanted to get rid of the aches and pains that come with aging. So when he was told about a stem cell procedure, he agreed to the treatment, for which he paid 16,000 euros (P854,000), in the hope that it would rejuvenate him and make him live longer. Instead, he felt weaker and feared the procedure even put his life at risk. Alleging that he was duped into what he now described as a bogus stem cell treatment at a posh hotel in Mandaluyong City, Villar had asked the police to investigate the group, composed mostly of foreigners, whom he blamed for his failing health. On Thursday, Villar sent his lawyer, Claire Pagayanan, to a news forum to announce that he was considering filing charges against a German, three Thais and their Filipino agent for the fake stem cell procedure he went through on June 9 last year. Pagayanan said that after the treatment, Villars prostate gland expanded and he had to undergo radiation … Continue reading →

A German national and his Thai cohorts are being pursued by Philippine authorities for allegedly conducting a bogus stem cell therapy on a government official for the price of P840,000. Senior Superintendent Francisco Esguerra of the Criminal Investigation and Detection Group (CIDG) said they are already coordinating with the victim, Dangerous Drugs Board chairman Antonio Villar, for their investigation. We immediately coordinated with the PMA [Philippine Medical Association] and through their help, we were able to convince him [Villar] to file a case, said Esguerra, who heads the Anti-Fraud and Commercial Crime Division of the CIDG. Stem cell therapy has been blamed for the deaths of three politicians, according to the Philippine Medical Association (PMA), as it warned the public against unaccredited foreign doctors who are conducting the treatment usually in five-star hotels. Esguerra said Villar told them that he met the supposed German physician through a Filipino middleman, who had told him that stem cell therapy would make him feel young. Apparently, he had been hearing about the positive results of stem cell therapy and that is the reason why he agreed, said Esguerra, recalling his conversation with Villar on Wednesday. He was expecting that he would feel young … Continue reading →

LONDON - Two men with HIV have been off AIDS drugs for several months after receiving stem-cell transplants for cancer that appear to have cleared the virus from their bodies, researchers reported on Wednesday. Both patients, who were treated in Boston and had been on long-term drug therapy to control their HIV, received stem-cell transplants after developing lymphoma, a type of blood cancer. Since the transplants, doctors have been unable to find any evidence of HIV infection, Timothy Henrich of Harvard Medical School and Brigham and Women's Hospital in Boston told an International AIDS Society conference in Kuala Lumpur. While it is too early to say for sure that the virus has disappeared from their bodies altogether, one patient has now been off antiretroviral drug treatment for 15 weeks and the other for seven weeks. Last July Henrich first reported that the two men had undetectable levels of HIV in their blood after their stem-cell treatment, but at that time they were still taking medicines to suppress HIV. Using stem-cell therapy is not seen as a viable option for widespread use, since it is extremely expensive, but the latest cases could open new avenues for fighting the disease, which infects … Continue reading →

Manila, Philippines --- A government official has sought the aid of the Criminal Investigation and Detection Group (CIDG) to investigate doctors who performed stem cell therapy on him which left him "weaker." A lawyer for Dangerous Drugs Board Chairman Antonio Villar told a media forum yesterday that he is bent on filing charges against the foreign medical team who performed the controversial medical procedure on him at a posh hotel. "We must first have an investigation on the matter prior to our filing of criminal raps against the three foreign doctors and other individuals who performed the therapy at a five-star hotel in Mandaluyong," said lawyer Claire Pagayanan said. "The lead doctor was from Germany while the other two doctors and some nurses who assisted them were from Thailand," Pagayanan said. Senior Supt. Francisco Esguerra, head of the CIDG-Anti-Fraud and Commercial Crime Division, confirmed that Villar is seeking an investigation into the medical team for allegedly performing a bogus stem cell treatment that cost him 15,000 euros. Esguerra said they expect to identify the foreign suspects and their Filipino cohort in the coming days since Villar has already agreed to cooperate in the investigation. "We immediately coordinated with the PMA … Continue reading →

PARIS--(BUSINESS WIRE)-- Regulatory News: BioAlliance Pharma SA (BIO.PA) (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, today announced funding of almost 9 million from bpifrance through a Strategic Industrial Innovation (ISI) program. An amount of 4.3 million will be allocated directly to BioAlliance Pharma to accelerate the industrial development of Livatag. This grant supports the launch of NICE (Nano Innovation for Cancer), the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization of processes specific to nanodrugs. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org). Consisting of five public and private partners and led by BioAlliance Pharma, the NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner. Developed by BioAlliance Pharma, Livatag, a doxorubicin nanoparticle currently in phase III trial for the treatment of primary liver cancer, will fully benefit from this platform of expertise and the grant awarded by bpifrance will help … Continue reading →

GRENOBLE, France--(BUSINESS WIRE)-- CEA-Leti announced today 1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815. The grant, awarded through bpifrance s Strategic Industrial Innovation (ISI) program, will accelerate the development of LipImage 815, including production and regulatory toxicity evaluation. It also supports the launch of NICE (Nano Innovation for Cancer), the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org). Developed by Leti, LipImage 815 is a fluorescent imaging agent based on Letis Lipidots platform that uses lipid nanoparticles to carry a fluorescent substance to targeted cells and improve the effectiveness of diagnosis. It will be used to test for early stages of liver cancer. Consisting of five public and private partners and led by BioAlliance Pharma, the NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner. In addition to Leti, the consortium includes: By bringing … Continue reading →